Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the early 2000s, under the leadership of Professor Adrian Hill, the Jenner Institute performed several clinical trials of candidate malaria vaccines. These tested a series of different emerging vaccine technologies.

The most promising results were obtained using a disabled version of an adenovirus (a type of common cold virus – in this case, one which affects chimpanzees rather than people) 1. That vaccine candidate had been developed in partnership with an Italian company, Okairos 2,3, building on the pioneering work of Hildegund Ertl, James Wilson and colleagues in Philadelphia. The chimpanzee adenovirus-based malaria vaccine was partially effective, and Okairos was later taken over by the major pharmaceutical company, GSK.

In parallel with the work on malaria with Okairos, the Jenner initiated a project to produce its own chimpanzee adenovirus vaccine platform ‘in house’, giving it the freedom to apply the promising technology to multiple other diseases, independent of any industrial partner. Hill contacted a Swedish scientist, Göran Wadell, who had collected a set of samples of adenoviruses from chimpanzees.

Starting from a sample of a virus known as ‘Y25’ provided by Wadell, a Jenner graduate student (Matthew Dicks, working with senior virologist Matthew Cottingham) created and performed early testing of the ‘ChAdOx1’ vector 4. ChAdOx1 differed from Y25 in that key genes needed for the virus to multiply in human cells were completely deleted, and in that Dicks exchanged one of the Y25 virus’ ‘non-structural’ genes for one from a human adenovirus, which would make the virus easier to manufacture.

Over this time, the Jenner had developed the infrastructure and organisational capability to produce and test multiple adenovirus-vectored vaccines against a range of diseases. Support from the Wellcome Trust allowed the establishment of a ‘Viral Vector Core Facility’ which could make small quantities of many new vaccines for early pre-clinical tests. Hill led re-purposing of the University’s Clinical Biomanufacturing Facility, which had been set up in the 1990s by Geoff Hale and colleagues to manufacture ‘clinical grade’ monoclonal antibodies, to instead make vaccines for first-time-in-human clinical trials.

Putting these capabilities together with the clinical trial expertise built by the malaria programme provided an ‘end-to-end pipeline’ which allowed candidate vaccines to be taken from the drawing board, through laboratory studies, into clinical trials in the UK and Africa.

Multiple Jenner researchers made use of this pipeline to develop and test chimpanzee adenovirus vectors against a range of diseases. Examples included further malaria vaccines (led by Simon Draper5-7), influenza (led by Sarah Gilbert8) and tuberculosis (led by Helen McShane9). Hill & Gilbert founded a spinout company, Vaccitech Ltd, which licensed the right to use the technology for certain diseases.

In 2014, during the West African Ebola outbreak, the Jenner was involved in the first ever clinical trial of an Ebola vaccine, a chimpanzee adenovirus-based vaccine which had been developed by the US National Institutes of Health and Okairos, then acquired by GSK. Using the organisational platform and experience built up by its previous work with similar vaccines, the Jenner team was able to contribute to getting the first trial participants vaccinated very quickly.

Following the Ebola outbreak, international research funders established the Coalition for Epidemic Preparedness Initiatives (CEPI) to develop vaccines against other viruses which might cause future outbreaks. The UK Vaccines Network channelled government funding into similar projects within the UK.

Applying the Jenner’s ChAdOx1 platform to such diseases was a logical step. Arturo Reyes-Sandoval, Sarah Gilbert, Teresa Lambe and George Warimwe each led development of ChAdOx1-based vaccines targeting CEPI priority pathogens 10-14. A team led by Sandy Douglas developed a simple method of manufacturing any vaccine based upon the ChAdOx platform, choosing techniques suitable for scale-up and transfer to larger-scale manufacturing facilities if required in an outbreak 15.




1.           O'Hara GA, Duncan CJ, Ewer KJ, et al. Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. J Infect Dis 2012; 205(5): 772-81.

2.           Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4(115): 115ra2.

3.           Reyes-Sandoval A, Berthoud T, Alder N, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. InfectImmun 2010; 78(1): 145-53.

4.           Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 2012; 7(7): e40385.

5.           Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011; 19(12): 2269-76.

6.           Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. Plos One 2012; 7(2): e31208.

7.           Payne RO, Silk SE, Elias SC, et al. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight 2017; 2(21).

8.           Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Molecular therapy : the journal of the American Society of Gene Therapy 2014; 22(3): 668-74.

9.           Stylianou E, Griffiths KL, Poyntz HC, et al. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine 2015; 33(48): 6800-8.

10.         Lopez-Camacho C, Abbink P, Larocca RA, et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat Commun 2018; 9(1): 2441.

11.         Folegatti PM, Harrison K, Preciado-Llanes L, et al. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun 2021; 12(1): 4636.

12.         Purushotham J, Lambe T, Gilbert SC. Vaccine platforms for the prevention of Lassa fever. Immunol Lett 2019; 215: 1-11.

13.         Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AVS, Lambe T. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human vaccines & immunotherapeutics 2017; 13(12): 3020-32.

14.         Warimwe GM, Gesharisha J, Carr BV, et al. Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Sci Rep 2016; 6: 20617.

15.         Fedosyuk S, Merritt T, Peralta-Alvarez MP, et al. Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components. Vaccine 2019.